HomeTrending EquitiesEditas Medicine (EDIT) Stock Rose 85% Since Release Of Positive Results Of...

Editas Medicine (EDIT) Stock Rose 85% Since Release Of Positive Results Of Its New Research

The biotechnology company Editas Medicine Inc. (EDIT) stock rose more than 85% since its announcement of new data on the successful EDIT-301 gene therapy trial on December 7.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The company focused on progress in preclinical trials of EDIT-301 at the annual meeting of the American Society of Hematology (ASH), which was held on Saturday, 5 December 2020. High levels of red blood cell editing obtained from patients with and without sickle cell anemia were achieved in particular. As a result of this it is necessary to achieve a significant degree of correction in cells with anemia, resulting in a stable induction of foetal hemoglobin. This could mean treating the disease in the future if the EDIT-301 production is successfully completed and approved as a treatment.

Most notably, Editas argues that its manufacturing method, sufficient for clinical scaling, has proven its efficiency. This is a promising indication for long-term investors, as gene therapy, which is appropriate for many patients and not only as an expensive personalized medicine, has the greatest commercial potential.

In the development of therapies for the treatment of sickle cell anemia, Editas is currently lagging behind its rivals, but plans to potentially deliver a cheaper, more reliable and safer therapy. As a result the company is able to gain a large market share for the treatment of this disease, as well as the funds required to conduct further research.

At the moment, Editas does not have an approved product in its portfolio. Therefore the growth of its pipeline remains a key priority. Still, compared to the 5.9 percent growth of the sector, the stock has increased 116 percent in the year so far.

Editas Medicine Inc. (EDIT) stock was down -1.45% to $63.99 on Wednesday but was up 26.51 percent over the week, raising its market capitalization to $4.31 billion.

Peggy Goldman
Peggy Goldman, CFA, is an independent monetary author and speculator. I have worked for both sell-side and purchase side firms (values and fixed salary), with the biggest level of my working time spent in drug tech. Now I am presently viably in a “working retirement”.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

WE HAVE A GIFT FOR YOU

SPECIAL GIFT

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

WE HAVE A GIFT FOR YOU

SPECIAL GIFT

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam